Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Rubio MJ, Fariñas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcón J, Follana P, Romero I, Lebreton C, Pérez-Fidalgo JA, Yunokawa M, Dahlstrand H, D'Hondt V, Randall LM; ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030 Investigators. Oaknin A, et al. Among authors: takekuma m. Lancet. 2024 Jan 6;403(10421):31-43. doi: 10.1016/S0140-6736(23)02405-4. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048793 Clinical Trial.
What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study.
Nagao S, Nishio S, Okada S, Otsuki T, Fujiwara K, Tanabe H, Takano M, Hasumi Y, Takei Y, Hasegawa T, Matsumoto T, Fujiwara K, Takekuma M, Nakamura K, Shimada M, Suzuki M, Kigawa J. Nagao S, et al. Among authors: takekuma m. Cancer Chemother Pharmacol. 2015 Aug;76(2):335-42. doi: 10.1007/s00280-015-2793-9. Epub 2015 Jun 20. Cancer Chemother Pharmacol. 2015. PMID: 26092322
Investigation of clinicopathological features of vulvar cancer in 1068 patients: A Japanese Gynecologic Oncology Group (JGOG) nationwide survey study.
Nishio S, Murotani K, Nakao S, Takenaka M, Suzuki S, Aoki Y, Todo Y, Hosaka M, Nakai H, Katabuchi H, Nishi H, Takekuma M, Mikami M, Enomoto T. Nishio S, et al. Among authors: takekuma m. Gynecol Oncol. 2020 Nov;159(2):449-455. doi: 10.1016/j.ygyno.2020.08.019. Epub 2020 Aug 25. Gynecol Oncol. 2020. PMID: 32854973
Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy.
Takekuma M, Takahashi F, Mabuchi S, Kudaka W, Horie K, Ikeda M, Shikama A, Mitsuhashi A, Nagao S, Suzuki S, Mizuno M, Nishio S, Tokunaga H, Ota Y, Kasamatsu T, Kitagawa R, Toita T, Kobayashi H, Ishikawa M, Yaegashi N. Takekuma M, et al. BMC Cancer. 2020 Nov 30;20(1):1169. doi: 10.1186/s12885-020-07672-w. BMC Cancer. 2020. PMID: 33256667 Free PMC article.
A retrospective assessment of the safety and efficacy of laparoscopic radical hysterectomy in Japan during the early years following its introduction: a Japanese Gynecologic Oncology Group study (JGOG1081S).
Kobayashi E, Kanao H, Takekuma M, Nishio S, Kojima-Chiba A, Tozawa A, Yamaguchi S, Takeshima N, Nakatani E, Mikami M. Kobayashi E, et al. Among authors: takekuma m. Int J Clin Oncol. 2021 Feb;26(2):417-428. doi: 10.1007/s10147-020-01799-3. Epub 2021 Jan 12. Int J Clin Oncol. 2021. PMID: 33433752
A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese Gynecologic Oncology Group study (JGOG1082).
Furusawa A, Takekuma M, Mori K, Usami T, Kondo E, Nishio S, Nishino K, Miyamoto Y, Yoshimura R, Watanabe M, Mikami M, Enomoto T. Furusawa A, et al. Among authors: takekuma m. Int J Gynecol Cancer. 2021 Apr;31(4):623-626. doi: 10.1136/ijgc-2020-002344. Epub 2021 Mar 4. Int J Gynecol Cancer. 2021. PMID: 33664127 Clinical Trial.
A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis.
Ishikawa M, Shibata T, Iwata T, Nishio S, Takada T, Suzuki S, Horie K, Kudaka W, Kagabu M, Tanikawa M, Kitagawa R, Takekuma M, Kobayashi H, Yaegashi N; Japan Clinical Oncology Group. Ishikawa M, et al. Among authors: takekuma m. Gynecol Oncol. 2021 Aug;162(2):292-298. doi: 10.1016/j.ygyno.2021.05.007. Epub 2021 May 18. Gynecol Oncol. 2021. PMID: 34016453 Clinical Trial.
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yañez E, Gümüş M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Toker S, Li K, Keefe SM, Monk BJ; KEYNOTE-826 Investigators. Colombo N, et al. N Engl J Med. 2021 Nov 11;385(20):1856-1867. doi: 10.1056/NEJMoa2112435. Epub 2021 Sep 18. N Engl J Med. 2021. PMID: 34534429 Clinical Trial.
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826.
Nishio S, Yonemori K, Usami T, Minobe S, Yunokawa M, Iwata T, Okamoto A, Aoki Y, Itamochi H, Takekuma M, Harano K, Yamamoto K, Maruko T, Ugai H, Tekin C, Colombo N, Fujiwara K, Hasegawa K, Ushijima K. Nishio S, et al. Among authors: takekuma m. Cancer Sci. 2022 Nov;113(11):3877-3887. doi: 10.1111/cas.15479. Epub 2022 Sep 15. Cancer Sci. 2022. PMID: 35792064 Free PMC article. Clinical Trial.
78 results